Medical Device Maker Ambu Launches New Single-Use Cystoscope for Improved Workflow and Enhanced Productivity Benefits

Ambu Inc., a rapidly growing medical device maker and pioneer of sterile, single-use endoscopes, introduced today a new single-use cystoscope.

The Ambu aScope™ 4 Cysto will give urologists immediate access to a single-use cystoscope that can be used for procedures such as bladder cancer surveillance, stent removal and other common cystoscopy procedures.

Built on more than 10 years of single-use endoscopy experience, the launch of the aScope 4 Cysto enables Ambu to enter a large new market segment. Its new cystoscope will provide urologists a way to better manage their schedules and be more productive without worrying about device deterioration and other issues such as availability, reprocessing and costly repairs.

“This is a game changer,” said Juan Jose Gonzalez, CEO of Ambu S/A, headquartered in Ballerup, Denmark. “Urologists will now have immediate access to a high-quality scope that eliminates reprocessing and repairs. A urologist opens the package and immediately has a new scope offering peak performance with full articulation. They don’t have to wait and worry whether a scope will be available or whether it will work properly.”

The aScope 4 Cysto enables organizations to reduce costs on cleaning supplies, maintenance and repairs (and the associated long-term service contracts). It improves workflow and is portable, which makes it easier for doctors to deal with in-house consult procedures.

“The Cystoscope is a multi-purpose tool used by all urologists; therefore, we are excited to introduce the aScope 4 Cysto which affords urologists excellent imaging, smooth maneuverability, and consistent performance every time,” said Jens Kemp, Ambu Inc.’s vice president of U.S. marketing.  “It is a perfect solution for both flexible cystoscopies performed in the outpatient clinic as well as inpatient consults on the ward and ER. “

aView 2 Advance

Ambu, already the world leader in single-use scopes, is ramping up manufacturing to provide a single-use endoscope solution in multiple flexible endoscopy segments, including Pulmonology, ENT, Urology and Gastroenterology. In conjunction with the aScope 4 Cysto and additional endoscopes coming to market, Ambu also recently introduced  its aView™ 2 Advance, a state-of-the-art, high-definition monitor. This mobile platform can be used by pulmonologists, ENTs, urologists, thoracic surgeons, intensive care specialists and other specialists who perform millions of endoscopy procedures each year.

Ambu launched the world’s first single-use flexible bronchoscope, the Ambu® aScope™ in 2009. Ten years later, in 2019, over 600,000 Ambu single-use endoscopes were used in more than 3,500 hospitals making Ambu the world’s largest supplier of single-use endoscopes. The aScope Cysto builds on this history of innovation and close collaboration with healthcare professionals.

SourceAmbu

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”